Raymond James set a USD 140.00 target for Kymera Therapeutics stock

Published on 10/14/2026 at 03:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Citi lifted its target to USD 150.00 from USD 135.00 on October 5, 2026. For Kymera Therapeutics stock, revenue reached USD 65.00 million in June 2026.

Analyst targets and quarterly results

Coverage began with a USD 140.00 target from Raymond James on October 8, 2026.
Citi lifted its target from USD 135.00 to USD 150.00 on October 5, 2026.
Revenue reached USD 65.00 million in the quarter reported on August 5, 2026, up 465.20 percent year over year.

KYMR, US5015751044, Illustration mit AI erstellt.

Kymera Therapeutics (ISIN US5015751044) had a USD 140.00 price target set by Raymond James. As MarketBeat reported on October 10, 2026, the brokerage initiated coverage with an Outperform rating and a USD 140.00 target. The move adds a fresh valuation reference as Kymera advances its targeted protein degradation pipeline.

Three dated valuation signals

On August 5, 2026, Kymera reported quarterly revenue of USD 65.00 million and an adjusted loss of USD 0.62 per share, compared with an expected adjusted loss of USD 0.71, according to MarketBeat. On October 5, 2026, Citi raised its target from USD 135.00 to USD 150.00 while keeping a Buy rating, as reported by Markets Insider. Raymond James followed on October 8, 2026, with its USD 140.00 target and Outperform rating.

What supports the valuation?

The second-quarter revenue figure represented 465.20 percent year-over-year growth, according to MarketBeat, while the reported adjusted loss was narrower than the USD 0.71 consensus estimate. That combination gives the analyst targets a measurable operating reference, although the company remains a clinical-stage biotechnology business.

Markets Insider reported that Citi linked its October 5, 2026 target increase to the expected KT-621 readout in atopic dermatitis. The same report said the Phase 2b BROADEN2 results were expected by the end of 2026, making the program a central milestone for the valuation.

Pipeline milestones shape the case

Kymera says its strategy combines targeted protein degradation with disease biology to develop oral medicines for chronic inflammatory diseases, according to its investor-relations overview. The company identifies the latest reported period as the second quarter of 2026 and lists clinical milestones ahead across its immunology portfolio.

Nasdaq context for KYMR

On the Nasdaq, KYMR was last at USD 106.68 on October 13, 2026 at 4:00 p.m. EDT. The same dated market snapshot placed the 52-week range at USD 55.26 to USD 130.05 and market capitalization at USD 8.8 billion.